Rational Pharmacotherapy in Cardiology

Advanced search

Nutraceutical support in the prevention and treatment of cardiovascular diseases



Cardiovascular disease is the most common cause of death worldwide. In this regard, there is a need to find and implement effective methods for the prevention and treatment of such diseases. Lifestyle modification is an important component of a complex of preventive and therapeutic measures, including nutrition optimization, increased physical activity, and breaking bad habits. Currently, an actively developing area is the use of biologically active additives to food, in order to replenish the missing nutrients in the diet and maintain health. In the course of the present review, an analysis was made of randomized clinical trials performed over the past 5 years. The studies investigated both the short-term effects of taking omega-3 polyunsaturated fatty acids (effect on the blood lipid spectrum, blood pressure levels) and longterm results (development of myocardial infarction, stroke, cardiovascular mortality). This supplement has demonstrated a positive effect on immediate outcomes, namely the reduction of total cholesterol, low-density lipoprotein, triglycerides (lipid-lowering effect). However, there was no significant effect on long-term results. It also provides information on studies that have examined the cardioprotective effects of supplements such as resveratrol, red yeast rice, L-arginine, and curcumin. An analysis of publications has shown that these supplements have the potential to reduce the risk of development and progression of cardiovascular diseases due to possible hypolipidemic, endothelial protective, and antihypertensive effects. Nutraceutical support can be an effective addition to the basic treatment and help reduce morbidity and mortality due to cardiovascular disease.

About the Authors

E. V. Gracheva
Siberian State Medical University
Russian Federation

Elena V. Gracheva


E. A. Starovoytova
Siberian State Medical University

Elena A. Starovoytova


E. S. Kulikov
Siberian State Medical University
Russian Federation

Evgeny S. Kulikov


N. A. Kirillova
Siberian State Medical University
Russian Federation

Natalya A. Kirillova


S. V. Fedosenko
Siberian State Medical University
Russian Federation

Sergey V. Fedosenko


M. A. Balaganskaya
Siberian State Medical University
Russian Federation

Marina A. Balaganskaya


D. V. Kromka
Siberian State Medical University
Russian Federation

Danila V. Kromka



1. Drapkina O. M., Karamnova N. S., Kontsevaya A. V., al. Russian Society for the Prevention of Noncommunicable Diseases (ROPNIZ). Alimentary-dependent risk factors for chronic non-communicable diseases and eating habits: dietary correction within the framework of preventive counseling. Methodological Guidelines. Cardiovascular Therapy and Prevention. 2021;20(5):2952. (In Russ.) DOI: 10.15829/1728-8800-2021-2952.

2. Manson JE, Cook NR, Lee IM, et al. Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer. N Engl J Med. 2019;380(1):23-32. DOI:10.1056/NEJMoa1811403.

3. ASCEND Study Collaborative Group, Bowman L, Mafham M, et al. Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus. N Engl J Med. 2018;379(16):15401550. DOI:10.1056/NEJMoa1804989.

4. Kalstad AA, Myhre PL, Laake K, et al. Effects of n-3 Fatty Acid Supplements in Elderly Patients After Myocardial Infarction: A Randomized, Controlled Trial. Circulation. 2021;143(6):528-539. DOI:10.1161/CIRCULATIONAHA.120.052209.

5. Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. JAMA. 2020;324(22):2268-2280. DOI:10.1001/jama.2020.22258.

6. Matsumoto C, Yoruk A, Wang L, et al. Fish and omega-3 fatty acid consumption and risk of hypertension. J Hypertens. 2019;37(6):1223-1229. DOI:10.1097/HJH.0000000000002062.

7. Bhatt DL, Steg PG, Miller M, et al. Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT. J Am Coll Cardiol. 2019;73(22):2791-2802. DOI:10.1016/j.jacc.2019.02.032.

8. Yuan M, Zhang Y, Hua T, et al. Omega-3 polyunsaturated fatty acid supplementation improves lipid metabolism and endothelial function by providing a beneficial eicosanoid-pattern in patients with acute myocardial infarction: A randomized, controlled trial. Clin Nutr. 2021;40(2):445-459. DOI:10.1016/j.clnu.2020.05.034.

9. Stroes ESG, Susekov AV, de Bruin TWA, et al. Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial. J Clin Lipidol. 2018;12(2):321-330. DOI:10.1016/j.jacl.2017.10.012.

10. Jun JE, Jeong IK, Yu JM, et al. Efficacy and Safety of Omega-3 Fatty Acids in Patients Treated with Statins for Residual Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Diabetes Metab J. 2020;44(1):7890. DOI:10.4093/dmj.2018.0265.

11. Teplova VV, Isakova EP, Klein OI, et al. Natural polyphenols: biological activity, pharmacological potential, means of metabolic engineering. Applied Biochemistry and Microbiology. 2018;54(3):221-237 (In Russ.) DOI:10.1134/S0003683818030146.

12. Moiseeva AM, Zheleznyak NV, Generalova AG, Moiseev DV. Phytoalexin resveratrol:assays, mechanism of action, perspective of clinical use. Vestnik farmacii. 2012; 1(55):63-73 (In Russ.)

13. Chekalina NI. Resveratrol has a positive effect on parameters of central hemodynamics and myocardial ischemia in patients with stable coronary heart disease. Wiad Lek. 2017;70(2 pt 2):286-291.

14. Simental-Mendía LE, Guerrero-Romero F. Effect of resveratrol supplementation on lipid profile in subjects with dyslipidemia: A randomized double-blind, placebo-controlled trial. Nutrition. 2019;58:7-10. DOI:10.1016/j.nut.2018.06.015.

15. Marques BCAA, Trindade M, Aquino JCF, et al. Beneficial effects of acute transresveratrol supplementation in treated hypertensive patients with endothelial dysfunction. Clin Exp Hypertens. 2018;40(3):218-223. DOI:10.1080/10641963.2017.1288741.

16. Gal R, Praksch D, Kenyeres P, et al. Hemorheological Alterations in Patients with Heart Failure with Reduced Ejection Fraction Treated by Resveratrol. Cardiovasc Ther. 2020;2020:7262474. DOI:10.1155/2020/7262474.

17. Endo A. Monacolin K. A new hypocholesterolemic agent produced by a Monascus species. J Antibiot (Tokyo). 1979;32(8):852–4.

18. Benjian C, Xiaodan H, Huiting P, et al. Effectiveness and safety of red yeast rice predominated by monacolin K β-hydroxy acid form for hyperlipidemia treat- ment and management. J Tradit Chin Med. 2022;42(2):264-271. DOI:10.19852/j.cnki.jtcm.2022.02.007.

19. Minamizuka T, Koshizaka M, Shoji M, et al. Low dose red yeast rice with monacolin K lowers LDL cholesterol and blood pressure in Japanese with mild dyslipidemia: A multicenter, randomized trial. Asia Pac J Clin Nutr. 2021;30(3):424-435. DOI:10.6133/apjcn.202109_30(3).0009.

20. Wang TJ, Lien AS, Chen JL, et al. A Randomized Clinical Efficacy Trial of Red Yeast Rice (Monascus pilosus) Against Hyperlipidemia. Am J Chin Med. 2019;47(2):323-335. DOI: 10.1142/S0192415X19500150.

21. Mazza A, Schiavon L, Rigatelli G, et al. The short-term supplementation of monacolin K improves the lipid and metabolic patterns of hypertensive and hypercholesterolemic subjects at low cardiovascular risk. Food Funct. 2018;9(7):3845-3852. DOI:10.1039/c8fo00415c.

22. Mazza A, Lenti S, Schiavon L, et al. Effect of Monacolin K and COQ10 supplementation in hypertensive and hypercholesterolemic subjects with metabolic syndrome. Biomed Pharmacother. 2018;105:992-996. DOI:10.1016/j.biopha.2018.06.076.

23. Souci SW, Fachmann W, Kraut H. Food composition and nutrition tables. 5th ed. Stuttgart: Medpharm Scientific Publisher; 1994.

24. Shiraseb F, Asbaghi O, Bagheri R, et al. Effect of l-Arginine Supplementation on Blood Pressure in Adults: A Systematic Review and Dose-Response Meta-analysis of Randomized Clinical Trials. Adv Nutr. 2022;13(4):1226-1242. DOI:10.1093/advances/nmab155.

25. Salmani M, Alipoor E, Navid H, et al. Effect of l-arginine on cardiac reverse remodeling and quality of life in patients with heart failure. Clin Nutr. 2021;40(5):3037-3044. DOI:10.1016/j.clnu.2021.01.044.

26. Kostyuk VA. Biological activity of curcumin and perspectives for the pharmacological use. Journal of the Grodno State Medical University. 2022;20(2):144-151 (In Russ.) DOI:10.25298/2221-8785-2022-20-2-144-151.

27. Tabaee S, Sahebkar A, Aghamohammadi T, et al. The Effects of Curcumin Plus Piperine Supplementation in Patients with Acute Myocardial Infarction: A Randomized, Double-Blind, and Placebo-Controlled Trial. Adv Exp Med Biol. 2021;1328:199-211. DOI:10.1007/978-3-030-73234-9_13.

28. Aslanabadi N, Entezari-Maleki T, Rezaee H, et al. Curcumin for the prevention of myocardial injury following elective percutaneous coronary intervention; a pilot randomized clinical trial. Eur J Pharmacol. 2019;858:172471. DOI:10.1016/j.ejphar.2019.172471.

29. Campbell MS, Ouyang A, I M K, et al. Influence of enhanced bioavailable curcumin on obesity-associated cardiovascular disease risk factors and arterial function: A double-blinded, randomized, controlled trial. Nutrition. 2019;62: 135-139. DOI:10.1016/j.nut.2019.01.002.

30. Santos-Parker JR, Strahler TR, Bassett CJ, et al. Curcumin supplementation improves vascular endothelial function in healthy middle-aged and older adults by increasing nitric oxide bioavailability and reducing oxidative stress. Aging (Albany NY). 2017;9(1):187-208. DOI:10.18632/aging.101149.

Supplementary files


For citations:

Gracheva E.V., Starovoytova E.A., Kulikov E.S., Kirillova N.A., Fedosenko S.V., Balaganskaya M.A., Kromka D.V. Nutraceutical support in the prevention and treatment of cardiovascular diseases. Rational Pharmacotherapy in Cardiology. 2023;19(3):298-306. (In Russ.) EDN: WOTHWI

Views: 208

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)